Standout Papers

Everolimus for Advanced Pancreatic Neuroendocrine Tumors 2011 2026 2016 2021 2.0k
  1. Everolimus for Advanced Pancreatic Neuroendocrine Tumors (2011)
    James C. Yao, Manisha H. Shah et al. New England Journal of Medicine
  2. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial (2013)
    John J. Bissler, J.C. Kingswood et al. The Lancet

Immediate Impact

8 from Science/Nature 60 standout
Sub-graph 1 of 18

Citing Papers

Pancreatic cancer: Advances and challenges
2023 Standout
Metastasis
2023 Standout
3 intermediate papers

Works of Jeremie Lincy being referenced

Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
2011

Author Peers

Author Last Decade Papers Cites
Jeremie Lincy 1859 1661 660 1154 19 2.8k
Sakina Hoosen 2103 2116 559 1446 7 2.8k
Roeland F. de Wilde 2327 1541 1191 894 60 3.7k
C. Lombard Bohas 1658 1660 431 1157 17 2.2k
Irina A. Lubensky 1265 1205 1571 880 65 3.7k
Kwan Y. Wong 479 342 1087 1671 29 2.5k
Shem Patyna 1845 1517 532 1120 32 2.5k
Judith Klimovsky 1524 813 290 590 27 1.8k
Jan Harder 2158 1770 368 1298 27 2.9k
Margaret A. Ponder 1001 1198 1331 1177 25 4.1k
Irina A. Lubensky 630 518 1046 318 41 2.2k

All Works

Loading papers...

Rankless by CCL
2026